低合并症I期非小细胞肺癌患者选择立体定向体部放疗与手术的总生存比较
研究基于美国国家癌症数据库2012至2018年无合并症记录的临床I期非小细胞肺癌患者,比较手术与立体定向体部放疗的总生存。共纳入30658例,手术组24729例(80.7%),立体定向体部放疗组5929例(19.3%)。倾向性评分匹配后,手术组长期总生存优于立体定向体部放疗组(5年总生存率71.0% vs 41.8%,P<.001)。
要点
- 2012至2018年立体定向体部放疗使用比例从15.9%升至26.0%(P<.001)。
- 手术组30天和90天死亡率均高于立体定向体部放疗组(1.7% vs 0.3%;2.8% vs 1.7%,P均<.001)。
- 倾向性评分匹配后手术组5年总生存率优于立体定向体部放疗组(71.0% vs 41.8%,P<.001)。
核心结论
- 立体定向体部放疗在低合并症早期肺癌患者中的应用日益增多,但对于可能适合任一治疗的患者,长期总生存仍以手术更优。
研究设计与样本
- 基于美国国家癌症数据库的查询分析,纳入2012至2018年无合并症记录、接受手术切除(肺叶切除、肺段切除或楔形切除)或立体定向体部放疗的临床I期非小细胞肺癌患者,共30658例,其中手术组24729例(80.7%),立体定向体部放疗组5929例(19.3%)。
- 采用倾向性评分匹配队列比较围治疗期死亡率和5年总生存率。
- 重复进行倾向性评分匹配分析,仅纳入有记录拒绝推荐手术的立体定向体部放疗患者。
主要发现
- 2012至2018年间,接受立体定向体部放疗的患者比例从15.9%增加至26.0%(P<.001)。
- 手术切除组30天死亡率和90天死亡率均高于立体定向体部放疗组(1.7% vs 0.3%,P<.001;2.8% vs 1.7%,P<.001)。
- 在倾向性评分匹配患者中,总生存起初数月 favoring 立体定向体部放疗,但在1年前逆转,长期显著 favoring 手术治疗(5年总生存率,71.0% vs 41.8%;P<.001)。
- 仅纳入有记录拒绝推荐手术的立体定向体部放疗患者重复倾向性评分匹配分析,仍显示手术治疗5年总生存更优(71.4% vs 55.9%;P<.001)。
关键数值与推荐
- 手术组与立体定向体部放疗组30天死亡率分别为1.7%和0.3%(P<.001),90天死亡率分别为2.8%和1.7%(P<.001)。
- 倾向性评分匹配队列5年总生存率手术组71.0% vs 立体定向体部放疗组41.8%(P<.001)。
- 仅纳入拒绝手术患者的倾向性评分匹配队列5年总生存率手术组71.4% vs 立体定向体部放疗组55.9%(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate trends in the utilization of stereotactic body radiotherapy (SBRT) and to compare overall survival (OS) of patients with early-stage non-small cell lung cancer (NSCLC) undergoing SBRT versus those undergoing surgery. METHODS: The National Cancer Database was queried for patients without documented comorbidities who underwent surgical resection (lobectomy, segmentectomy, or wedge resection) or SBRT for clinical stage I NSCLC between 2012 and 2018. Peritreatment mortality and 5-year OS were compared among propensity score-matched cohorts. RESULTS: A total of 30,658 patients were identified, including 24,729 (80.7%) who underwent surgery and 5929 (19.3%) treated with SBRT. Between 2012 and 2018, the proportion of patients receiving SBRT increased from 15.9% to 26.0% (P < .001). The 30-day mortality and 90-day mortality were higher among patients undergoing surgical resection versus those receiving SBRT (1.7% vs 0.3%, P < .001; 2.8% vs 1.7%, P < .001). In propensity score-matched patients, OS favored SBRT for the first several months, but this was reversed before 1 year and significantly favored surgical management in the long term (5-year OS, 71.0% vs 41.8%; P < .001). The propensity score-matched analysis was repeated to include only SBRT patients who had documented refusal of a recommended surgery, which again demonstrated superior 5-year OS with surgical management (71.4% vs 55.9%; P < .001). CONCLUSIONS: SBRT is being increasingly used to treat early-stage lung cancer in low-comorbidity patients. However, for patients who may be candidates for either treatment, the long-term OS favors surgical management.
引用
- Udelsman BV, Canavan ME, Zhan PL, et al. Overall survival in low-comorbidity patients with stage I non-small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. J Thorac Cardiovasc Surg. 2023. PMID: 37500052. doi:10.1016/j.jtcvs.2023.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。